--- title: "Nanobiotix SA (NANO) stock: news and investor profile" url: "https://aibio.space/companies/nanobiotix/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Nanobiotix SA (EURONEXT: NANO), France. The directory classifies it as Pharmaceuticals: Major." --- NANO Nanobiotix SA EURONEXT · France # Nanobiotix SA (NANO) news Financings · 2026-09-24 ## [Nanobiotix reports €110.9 million cash after ~€86 million follow-on, runway into 2029](https://aibio.space/news/nanobiotix-reports-110-9-million-cash-after-86-million-follow-runway/) The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain. ## Latest Nanobiotix SA news We have not published a story on Nanobiotix SA yet. When there is news, it will appear here. ## Nanobiotix SA at a glance - **Ticker**: NANO - **Listing**: EURONEXT - **Country**: France - **Cash, Dec 31, 2025**: €52.8 million ### Related companies - [Poxel SA](https://aibio.space/companies/poxel/) EURONEXT: POXEL - [Adocia SA](https://aibio.space/companies/adocia/) EURONEXT: ADOC - [Sanofi SA](https://aibio.space/companies/sanofi/) EURONEXT: SAN - [Gensight Biologics SA](https://aibio.space/companies/gensight-biologics/) EURONEXT: SIGHT - [Valerio Therapeutics](https://aibio.space/companies/valerio-therapeutics/) EURONEXT: ALVIO - [Oncodesign Precision Medicine](https://aibio.space/companies/oncodesign-precision-medicine-s-a/) EURONEXT: ALOPM - [Nicox SA](https://aibio.space/companies/nicox/) EURONEXT: ALCOX - [Neovacs SA](https://aibio.space/companies/neovacs/) EURONEXT: ALNEV ### Also on EURONEXT - [Oxurion NV](https://aibio.space/companies/oxurion/) OXUR - [Hyloris Pharmaceuticals SA](https://aibio.space/companies/hyloris-pharmaceuticals/) HYL - [Sanofi SA](https://aibio.space/companies/sanofi/) SAN - [DBV Technologies SA](https://aibio.space/companies/dbv-technologies/) DBV - [Ipsen SA](https://aibio.space/companies/ipsen/) IPN - [MaaT Pharma](https://aibio.space/companies/maat-pharma/) MAAT ## What Nanobiotix SA does Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics. It has three platforms: the Nanoradioenhancer, designed to increase the tumor-killing effect of radiotherapy, the Nanoprimer, designed to enable extrahepatic delivery of innovative systemic therapies, and a neurological disease platform. Its most advanced candidate is JNJ-1900 (NBTXR3), which the company designed to address needs across lines of therapy in solid tumors. Janssen Pharmaceutica NV, a Johnson & Johnson company, holds a global licensing agreement for JNJ-1900 (NBTXR3) from July 2023, which the text describes as a $2.6B worldwide agreement. MD Anderson is a clinical research collaborator. The clinical pipeline prioritizes head and neck cancer in elderly patients ineligible for cisplatin-based chemotherapy, in the global randomized Phase 3 NANORAY-312 study sponsored by J&J. Other studies include the Phase 1b LUMIRAY study in head and neck cancer, the randomized Phase 2 CONVERGE study in inoperable Stage 3 lung cancer, and a randomized Phase 2/3 in soft tissue sarcoma. The Nanoprimer platform is at the preclinical stage and the neurological platform at the discovery stage. | Product or program | What it is | Stage | |---|---|---| | JNJ-1900 (NBTXR3) | Nanoparticle designed to increase the tumor-killing effect of radiotherapy | Phase 3 (NANORAY-312) | | Nanoprimer platform (Curadigm) | Lipid nanoparticles that temporarily occupy liver pathways to enable drug delivery | preclinical | | OOcuity neurological platform | Nanoparticles designed to interact with neuronal networks | discovery | Summarised from the company's [20-F filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/nbx-20251231.htm). ## Nanobiotix SA annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [€32.6 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | [-€7.2 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | | Research and development | [€23.1 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | [€40.5 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | | Net income (loss) | [-€24.0 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | [-€68.1 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | | Cash from operations | [-€33.4 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | [-€19.6 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | | Cash and equivalents | [€52.8 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | [€49.7 million](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €52.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nanobiotix SA What is the ticker symbol of Nanobiotix SA? Nanobiotix SA trades under the ticker NANO on EURONEXT. Where is Nanobiotix SA listed? Nanobiotix SA is listed on EURONEXT. Our directory also records these other listings: DUS:5NR; FWB:5NR; GETTEX:5NR; HAM:5NR; HAN:5NR; LS:A1J7EB; LSE:0QAV; LSX:A1J7EB; MUN:5NR; NASDAQ:NBTX; SWB:5NR; TRADEGATE:5NR; XETR:5NR. What is the SEC CIK of Nanobiotix SA? The SEC Central Index Key (CIK) for Nanobiotix SA is 1760854. Its filings are on SEC EDGAR. How many shares does Nanobiotix SA have outstanding? 48,410,068 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31. Which country or territory is Nanobiotix SA listed under? Our directory records Nanobiotix SA under France. What does Nanobiotix SA do? Our directory classifies Nanobiotix SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Nanobiotix SA? The ISIN recorded for Nanobiotix SA is FR0011341205. Does aibio.space cover Nanobiotix SA? aibio.space lists Nanobiotix SA among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nanobiotix SA incorporated? SEC records list its state or country of incorporation as I0. What does Nanobiotix SA develop? Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics. It has three platforms: the Nanoradioenhancer, designed to increase the tumor-killing effect of radiotherapy, the Nanoprimer, designed to enable extrahepatic delivery of innovative systemic therapies, and a neurological disease platform. What is JNJ-1900 (NBTXR3) from Nanobiotix SA? JNJ-1900 (NBTXR3): Nanoparticle designed to increase the tumor-killing effect of radiotherapy Stage: Phase 3 (NANORAY-312). What is Nanoprimer platform (Curadigm) from Nanobiotix SA? Nanoprimer platform (Curadigm): Lipid nanoparticles that temporarily occupy liver pathways to enable drug delivery Stage: preclinical. What is the latest Nanobiotix SA (NANO) stock news? Our latest story on Nanobiotix SA, dated Sep 24, 2026: "Nanobiotix reports €110.9 million cash after ~€86 million follow-on, runway into 2029". The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain. [Source](https://aibio.space/news/nanobiotix-reports-110-9-million-cash-after-86-million-follow-runway/). What is Nanobiotix SA's latest stock offering or financing news? Our latest financing story, dated Sep 24, 2026: "Nanobiotix reports €110.9 million cash after ~€86 million follow-on, runway into 2029". The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain. [Source](https://aibio.space/news/nanobiotix-reports-110-9-million-cash-after-86-million-follow-runway/). How long will Nanobiotix SA's cash last? From our story of Sep 24, 2026: The company says cash should fund operations into 2029 on its current plan. [Source](https://aibio.space/news/nanobiotix-reports-110-9-million-cash-after-86-million-follow-runway/). ## Investor discussion: Nanobiotix SA Members talk about Nanobiotix SA (NANO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nanobiotix SA, newest first. Each line links the filing it comes from. 1. 2026-09-24 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1760854/000117184326006217/exh_991.htm) 2. 2026-06-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1760854/000117184326003884/exh_991.htm) 3. 2026-05-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1760854/000114036126022247/ny20063216x1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:NANO on TradingView](https://www.tradingview.com/symbols/EURONEXT-NANO/). ## SEC filings and registration - **SEC name**: Nanobiotix S.A. - **CIK**: 1760854 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NBTX (Nasdaq), NNBXF (OTC) - **State or country of incorporation**: I0 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 60 RUE DE WATTIGNIES, PARIS, France, 75012 - **Phone**: 33140260470 - **Shares outstanding**: 48,410,068 as of 2025-12-31 (20-F filed 2026-03-31) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326006721/f6k_102026.htm) filed 2026-10-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326006335/f6k_100126.htm) filed 2026-10-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000176085426000006/nbx-20260630.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326006217/f6k_092426.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326006172/f6k_091826.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326006011/f6k_091326.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326005955/f6k_090926.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1760854/000117184326005734/f6k_082526.htm) filed 2026-08-25 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001760854), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nanobiotix SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker NANO, recorded under France. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nanobiotix SA - **Ticker**: NANO - **Listing**: EURONEXT - **Country or territory**: France - **Business scope**: Pharmaceuticals: Major - **ISIN**: FR0011341205 - **Other listed symbols**: DUS:5NR; FWB:5NR; GETTEX:5NR; HAM:5NR; HAN:5NR; LS:A1J7EB; LSE:0QAV; LSX:A1J7EB; MUN:5NR; NASDAQ:NBTX; SWB:5NR; TRADEGATE:5NR; XETR:5NR - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/EURONEXT-NANO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nanobiotix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nanobiotix SA (NANO) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/nanobiotix/